Revolution Medicines Inc. closed its IPO on the Nasdaq Global Select Market with $273.7 million in gross proceeds.

The Redwood City, Calif.-based drugmaker sold a total of 16.1 million common shares at $17 apiece. This includes an additional 2.1 million shares sold as underwriters fully exercised their overallotment option.

Revolution Medicines' common stock began trading on the exchange Feb. 13 under the ticker symbol RVMD.

The company previously said it plans to use the proceeds to fund the development of multiple programs that target cancers caused by mutations in the RAS genes, including RMC-4630 and SOS1, as well as selective inhibitor RMC-5552.

J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities were joint book-running managers for the offering.